A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein

Journal of Immunology

Volumn 157, Issue 1, 1996, Pages 239-246

  Dahl, A Maria ^a   Beverley, Peter C L ^a   Stauss, Hans J ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; SYNTHETIC PEPTIDE;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNITY; CELL STIMULATION; CELL TRANSFORMATION; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; TARGET CELL; TUMOR PROMOTION;

EID: 0029952513     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Boon, T., J. C. Cerottini, B. Van den Eynde, P. Van der Bruggen, and A. Van Pel. 1994. Tumor-antigens recognized by T-lymphocytes. Annu. Rev. Immunul. 12: 337.
2. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. de Plaen, B. van den Eynde, A Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643.
3. Traversari, C., P. van der Bruggen, I. F. Luescher, C. Lurquin, P. Chomez, A. Van Pel, E. de Plaen, A. Amar-Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176:1453.
4. Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff, Jr. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716.
5. Boel, P., C. Wildmann, M. L. Sensi, R. Brasseur, J. C. Renauld, P. Coulie, T. Boon, and P. van der Bruggen. 1995. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167.
6. Bakker, A. B. H., M. W. J. Schreurs, A. J. de Boer, Y. Kawakami, S. A. Rosenberg, G. J. Adema, and C. G. Figdor. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005.
7. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human-melanoma antigen recognized by autologous T-cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515.
8. Wölfel, T., A. Van Pel, V. Brichard, J. Schneider, B. Seliger, K. Meyer zum Büschenfelde, and T. Boon. 1994. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol. 24:759.
9. Arnold, B., C. Goodnow, H. Hengartner, and G. Hammerling. 1990. The coming of transgenic mice: tolerance and immune reactivity. Immunol. Today 11:69.
10. Arnold, B., G. Schonrich, and G. J. Hammerling. 1993. Multiple levels of peripheral tolerance. Immunol. Today 14:12.
11. Ohashi, P. S., S. Oehen, K. Buerki, H. Pircher, C. T. Ohashi, B. Odermatt, B. Malissen, R. M. Zinkernagel, and H. Hengartner. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65:305.
12. Harlan, D. M., H. Hengartner, M. L. Huang, Y. H. Kang, R. Abe, R. W. Moreadith, H. Pircher, G. S. Gray, P. S. Ohashi, G. J. Freeman, L. M. Nadler, C. H. June, and P. Aichele. 1994. Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. Proc. Natl. Acad. Sci. USA 91:3137.
13. Bartek, J., J. Bartkova, B. Vojtesek, Z. Staskova, J. Lukas, A. Rejthar, J. Kovarik, C. A. Midgley, J. V. Gannon, and D. P. Lane. 1991. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699.
14. Bartkova, J., J. Lukas, H. Muller, D. Lutzhoft, M. Strauss, and J. Bartek. 1994. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer 57:353.
15. Bueso Ramos, C. E., T. Manshouri, M. A. Haidar, Y. O. Huh, M. J. Keating, and M. Albitar. 1995. Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis. Leuk. Lymphoma 17:13.
16. b antigens determined with monoclonal antibodies and H-2 mutant mice. Proc. Natl. Acad. Sci. USA 79:4737.
17. Williams, D. B., B. H. Barber, R. A. Flavell, and H. Allen. 1989. Role of beta-2 microglobulin in the intracellular transport and surface expression of murine class I histocompatibility molecules. J. Immunol. 142:2796.
18. d antigen, the products of a third polymorphic locus of the mouse major histocompatibility complex. J. Immunol. 125: 2473.
19. Ljunggren, H.-G., and K. Kärre. 1985. Host resistance directed selectively against H-2 deficient lymphoma variants. J. Exp. Med. 162:1745.
20. Kärre, K., H.-G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 319:675.
21. Yang, Y., K. Früh, J. Chambers, J. B. Waters, L. Wu, T. Spies, and P. A. Peterson. 1992. Major histocompalibility complex (MHC) encoded HAM2 is necessary for antigenic peptide loading onto class I MHC molecules. J. Immunol. 267:11669.
22. Gorer, P. A. 1950. Studies in antibody response of mice to tumour inoculation. Br. J. Cancer 4:372.
23. van Pel, A., E. de Plaen, and T. Boon. 1985. Selection of highly transfectable variant from mouse mastocytoma P815. Somat. Cell Mol. Genet. 11:467.
24. Morgenstern, J. P., and H. Land. 1990. Advanced mammalian gene transfer: high titer retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18:3587.
25. Rhim, J. S., H. Y. Cho, and R. J. Huebner. 1975. Non-producer human cells induced by murine sarcoma virus. Int. J. Cancer 15:23.
26. Chakrabarti, S., K. Brechling, and B. Moss. 1985. Vaccinia virus expression vector coexpression of β-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5:3403.
27. Talavera, A., and J. M. Rodriguez. 1991. Isolation and handling of recombinant vaccinia viruses. In Methods in Molecular Biology, Vol. 8: Practical Molecular Virology. M. Collins, ed. The Humana Press, Clifton, p. 235.
28. Talavera, A., and J. M. Rodriguez. 1991. Vaccinia virus as an expression vector. In Methods in Molecular Biology, Vol. 8: Practical Molecular Virology. M Collins, ed. The Humana Press, Clifton, p. 219.
29. Stauss, H. J., H. Davies, E. Sadovnikova, B. Chain, N. Horowitz. and C. Sinclair. 1992. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. Proc. Natl. Acad. Sci. USA 89:7871.
30. Macatonia, S. E., P. M. Taylor, S. E. Knight, and B. A. Askonas. 1989. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J. Exp. Med. 169:1255.
31. Metlay, J. P., M. D. Witmer-Pack, R. Agger, M. T. Crowley, D. Lawless, and R. M. Steinman. 1990. The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J. Exp. Med. 171: 1753.
32. Bhattacharya, A., M. E. Dorf, and T. A. Springer. 1994. A shared alloantigenic determinant on Ia antigens encoded by the I-A and I-E subregions: evidence for I region gene duplication. J. Immunol 127:2488.
33. Ho, M.-K., and T. A. Springer. 1982. Mac-1 antigen: quantitative expression in macrophage populations and tissues, and immunofluorescent localization in spleen. J. Immunol. 128:2281.
34. Falk, K., and O. Rotzschke. 1993. Consensus motifs and peptide ligands of MHC class I molecules. Semin. Immunol. 5:81.
35. Janeway, C. A., Jr. 1992. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today 13:11.
36. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991.
37. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
38. Irvine, K. R., B. J. McCabe, S. A. Rosenberg, and N. P. Restifo. 1995. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J. Immunol. 154:4651.
39. Knuth, A., B. Danowski, H. F. Oettgen, and L. J. Old. 1984. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc. Natl. Acad. Sci. USA 81:3511.
40. Visseren, M. J., A. van-Elsas, E. I. van-der-Voort, M. E. Ressing, W. M. Kast, P. I. Schrier, and C. J. Melief. 1995. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J. Immunol. 154:3991.